Open Access Peer-reviewed Research Article

TAAR1 as a new target for the treatment of bipolar disorder: Anti-manic and anti-depressant activity of the novel agonist PCC0105004

Main Article Content

Linyao Yu
Wei Zhang
Yaoqin Shi
Yingtian Zhang
Min Xu
Yang Xu
Chunmei Li
Jingwei Tian corresponding author


Background: Bipolar disorder (BD) is a deleterious psychiatric disorder, and the available pharmacotherapies have limited efficacy with significant side effects. Trace amine-associated receptor 1 (TAAR1) is an emerging drug target for neuropsychiatric disorders such as schizophrenia and substance user disorders. However, it is unknown whether TAAR1 is involved in the pathogenesis of BD. This study examined the effects and underlying mechanisms of a novel TAAR1 agonist, PCC0105004, in a rat model of ouabain (OUA)-induced BD.
Methods: Intracerebroventricular (ICV) administration of OUA-induced BD model was established. The in vitro cell-based cAMP assay was used to examine TAAR1 agonism of PCC0105004. The receptor specificity of PCC0105004 was determined by an off-target panel assay that included radioligand binding and enzymatic assays. The effects of PCC0105004 on manic-like and depressive-like behaviors were evaluated in the rat BD model. TAAR1-mediated signaling and oxidative stress parameters were biochemically determined in the prefrontal cortex and the hippocampus of rats.
Results: Western blotting revealed reduced TAAR1 expression level in the prefrontal cortex but unchanged in the hippocampus in model rats. PCC0105004, a TAAR1 agonist with the agonism EC50 value of 0.06182 μM, attenuated the manic-like behaviors on the 7th day and the depressive-like behaviors on the 14th day at doses that did not affect locomotor activity in the BD rats. Mechanistically, PCC0105004 exerted its behavioral effects via the reduction of ROS damage through the phosphorylation activation of the TAAR1/Akt/GSK3β/BDNF signaling pathway.
Conclusion: These results demonstrated the potential antimanic-like and antidepressant-like efficacy of a novel TAAR1 agonist PCC0105004 in rats and revealed its underlying molecular basis, which supports the possibility of TAAR1 agonists as candidate pharmacotherapeutics for BD.

bipolar disorder, TAAR1, PCC0105004, prefrontal cortex, oxidative stress

Article Details

Supporting Agencies
This work was supported by the Natural Science Foundation of Shandong Province (No. ZR2020MH411).
How to Cite
Yu, L., Zhang, W., Shi, Y., Zhang, Y., Xu, M., Xu, Y., Li, C., & Tian, J. (2024). TAAR1 as a new target for the treatment of bipolar disorder: Anti-manic and anti-depressant activity of the novel agonist PCC0105004. Journal of Pharmaceutical and Biopharmaceutical Research, 5(1), 396-411.


  1. Burdick KE, Millett CE. Cognitive heterogeneity is a key predictor of differential functional outcome in patients with bipolar disorder. European Neuropsychopharmacology. 2021, 53: 4-6.
  2. Sparacino G, Verdolini N, Vieta E, et al. Existing and emerging pharmacological approaches to the treatment of mania: A critical overview. Translational Psychiatry. 2022, 12(1).
  3. Merikangas KR, Jin R, He JP, et al. Prevalence and Correlates of Bipolar Spectrum Disorder in the World Mental Health Survey Initiative. Archives of General Psychiatry. 2011, 68(3): 241.
  4. Lynn D J .Manic-Depressive Illness: Bipolar Disorders and Recurrent Depression, 2nd ed. The Journal of Clinical Psychiatry, 2009.
  5. McIntyre RS, Cha DS, Kim RD, et al. A review of FDA-approved treatment options in bipolar depression. CNS Spectrums. 2013, 18(s1): 1-21.
  6. Rutigliano G, Bräunig J, Del Grande C, et al. Non-Functional Trace Amine-Associated Receptor 1 Variants in Patients With Mental Disorders. Frontiers in Pharmacology. 2019, 10.
  7. Dedic N, Dworak H, Zeni C, et al. Therapeutic Potential of TAAR1 Agonists in Schizophrenia: Evidence from Preclinical Models and Clinical Studies. International Journal of Molecular Sciences. 2021, 22(24): 13185.
  8. Revel FG, Moreau JL, Gainetdinov RR, et al. Trace Amine-Associated Receptor 1 Partial Agonism Reveals Novel Paradigm for Neuropsychiatric Therapeutics. Biological Psychiatry. 2012, 72(11): 934-942.
  9. El-Mallakh RS, Wyatt RJ. The Na,K-ATPase hypothesis for bipolar illness. Biological Psychiatry. 1995, 37(4): 235-244.
  10. Jornada LK, Valvassori SS, Steckert AV, et al. Lithium and valproate modulate antioxidant enzymes and prevent ouabain-induced oxidative damage in an animal model of mania. Journal of Psychiatric Research. 2011, 45(2): 162-168.
  11. Broadhurst PL. The Place of Animal Psychology in the Development of Psychosomatic Research. Advances in Psychosomatic Medicine.: 63-69.
  12. Ericson E, Samuelsson J, Ahlenius S. Photocell measurements of rat motor activity. Journal of Pharmacological Methods. 1991, 25(2): 111-122.
  13. Giménez-Palomo A, Vieta E. The potential of TAAR1 agonists in bipolar disorder. European Neuropsychopharmacology. 2022, 62: 4-6.
  14. Traub, N, Lichtstein, et al. The Mood Cycle Hypothesis: Possible Involvement of Steroid Hormones in Mood Regulation by Means of Na+, K+-ATPase Inhibition. Journal of Basic and Clinical Physiology and Pharmacology. 2000, 11(4): 375-394.
  15. Weigand KM, Swarts HGP, Fedosova NU, et al. Na,K-ATPase activity modulates Src activation: A role for ATP/ADP ratio. Biochimica et Biophysica Acta (BBA) - Biomembranes. 2012, 1818(5): 1269-1273.
  16. Aperia A. New roles for an old enzyme: Na,K‐ATPase emerges as an interesting drug target. Journal of Internal Medicine. 2007, 261(1): 44-52.
  17. Nesher M, Shpolansky U, Rosen H, et al. The digitalis-like steroid hormones: New mechanisms of action and biological significance. Life Sciences. 2007, 80(23): 2093-2107.
  18. Machado-Vieira R, Kapczinski F, Soares JC. Perspectives for the development of animal models of bipolar disorder. Progress in Neuro-Psychopharmacology and Biological Psychiatry. 2004, 28(2): 209-224.
  19. Valvassori SS, Budni J, Varela RB, et al. Contributions of animal models to the study of mood disorders. Revista Brasileira de Psiquiatria. 2013, 35(suppl 2): S121-S131.
  20. Valvassori SS, Dal-Pont GC, Resende WR, et al. Validation of the animal model of bipolar disorder induced by Ouabain: face, construct and predictive perspectives. Translational Psychiatry. 2019, 9(1).
  21. Ashtari M, Cervellione K, Cottone J, et al. Corrigendum to “Diffusion abnormalities in adolescents and young adults with a history of heavy cannabis use” [Journal of Psychiatric Research 43 (2009) 189–204]. Journal of Psychiatric Research. 2009, 43(11): 1003.
  22. Valvassori SS, Tonin PT, Varela RB, et al. Lithium modulates the production of peripheral and cerebral cytokines in an animal model of mania induced by dextroamphetamine. Bipolar Disorders. 2015, 17(5): 507-517.
  23. Burchett SA, Hicks TP. The mysterious trace amines: Protean neuromodulators of synaptic transmission in mammalian brain. Progress in Neurobiology. 2006, 79(5-6): 223-246.
  24. Lindemann L, Hoener MC. A renaissance in trace amines inspired by a novel GPCR family. Trends in Pharmacological Sciences. 2005, 26(5): 274-281.
  25. Lindemann L, Meyer CA, Jeanneau K, et al. Trace Amine-Associated Receptor 1 Modulates Dopaminergic Activity. Journal of Pharmacology and Experimental Therapeutics. 2007, 324(3): 948-956.
  26. Bradaia A, Trube G, Stalder H, et al. The selective antagonist EPPTB reveals TAAR1-mediated regulatory mechanisms in dopaminergic neurons of the mesolimbic system. Proceedings of the National Academy of Sciences. 2009, 106(47): 20081-20086.
  27. Revel FG, Moreau JL, Gainetdinov RR, et al. TAAR1 activation modulates monoaminergic neurotransmission, preventing hyperdopaminergic and hypoglutamatergic activity. Proceedings of the National Academy of Sciences. 2011, 108(20): 8485-8490.
  28. Revel FG, Meyer CA, Bradaia A, et al. Brain-Specific Overexpression of Trace Amine-Associated Receptor 1 Alters Monoaminergic Neurotransmission and Decreases Sensitivity to Amphetamine. Neuropsychopharmacology. 2012, 37(12): 2580-2592.
  29. Revel FG, Moreau JL, Pouzet B, et al. A new perspective for schizophrenia: TAAR1 agonists reveal antipsychotic- and antidepressant-like activity, improve cognition and control body weight. Molecular Psychiatry. 2012, 18(5): 543-556.
  30. Pei Y, Lee J, Leo D, et al. Activation of the Trace Amine-Associated Receptor 1 Prevents Relapse to Cocaine Seeking. Neuropsychopharmacology. 2014, 39(10): 2299-2308.
  31. Thorn DA, Zhang C, Zhang Y, et al. The trace amine associated receptor 1 agonist RO5263397 attenuates the induction of cocaine behavioral sensitization in rats. Neuroscience Letters. 2014, 566: 67-71.
  32. Harmeier A, Obermueller S, Meyer CA, et al. Trace amine-associated receptor 1 activation silences GSK3$beta$ signaling of TAAR1 and D2R heteromers. European Neuropsychopharmacology. 2015, 25(11): 2049-2061.
  33. Chiou YJ, Huang TL. Brain-derived neurotrophic factor (BDNF) and bipolar disorder. Psychiatry Research. 2019, 274: 395-399.
  34. Barbosa IG, Huguet RB, Neves FS, et al. Impaired nerve growth factor homeostasis in patients with bipolar disorder. The World Journal of Biological Psychiatry. 2010, 12(3): 228-232.
  35. Barbosa IG, Huguet RB, Sousa LP, et al. Circulating levels of GDNF in bipolar disorder. Neuroscience Letters. 2011, 502(2): 103-106.
  36. Scola G, Andreazza AC. The role of neurotrophins in bipolar disorder. Progress in Neuro-Psychopharmacology and Biological Psychiatry. 2015, 56: 122-128.
  37. Wiener CD, Molina ML, Moreira FP, et al. Brief psychoeducation for bipolar disorder: Evaluation of trophic factors serum levels in young adults. Psychiatry Research. 2017, 257: 367-371.
  38. Lee YJ, Kim HR, Lee CY, et al. 2-Phenylethylamine (PEA) Ameliorates Corticosterone-Induced Depression-Like Phenotype via the BDNF/TrkB/CREB Signaling Pathway. International Journal of Molecular Sciences. 2020, 21(23): 9103.
  39. Tozzi F, Rutigliano G, Borsò M, et al. T1AM-TAAR1 signalling protects against OGD-induced synaptic dysfunction in the entorhinal cortex. Neurobiology of Disease. 2021, 151: 105271.
  40. Grimes CA, Jope RS. CREB DNA binding activity is inhibited by glycogen synthase kinase-3$beta$ and facilitated by lithium. Journal of Neurochemistry. 2001, 78(6): 1219-1232.
  41. Ren X, Rizavi HS, Khan MA, et al. Alteration of cyclic-AMP response element binding protein in the postmortem brain of subjects with bipolar disorder and schizophrenia. Journal of Affective Disorders. 2014, 152-154: 326-333.
  42. Berk M, Kapczinski F, Andreazza AC, et al. Pathways underlying neuroprogression in bipolar disorder: Focus on inflammation, oxidative stress and neurotrophic factors. Neuroscience & Biobehavioral Reviews. 2011, 35(3): 804-817.
  43. Barbosa IG, Rocha NP, Assis F, et al. Monocyte and Lymphocyte Activation in Bipolar Disorder: A New Piece in the Puzzle of Immune Dysfunction in Mood Disorders. International Journal of Neuropsychopharmacology. 2014, 18(1): pyu021-pyu021.
  44. Eom TY, Jope RS. Blocked Inhibitory Serine-Phosphorylation of Glycogen Synthase Kinase-3$alpha$/$beta$ Impairs In Vivo Neural Precursor Cell Proliferation. Biological Psychiatry. 2009, 66(5): 494-502.
  45. Beurel E, Jope RS. The paradoxical pro- and anti-apoptotic actions of GSK3 in the intrinsic and extrinsic apoptosis signaling pathways. Progress in Neurobiology. 2006, 79(4): 173-189.
  46. de Sousa RT, Zarate CA, Zanetti MV, et al. Oxidative stress in early stage Bipolar Disorder and the association with response to lithium. Journal of Psychiatric Research. 2014, 50: 36-41.
  47. Fernandes BS, Gama CS, Maria Ceresér K, et al. Brain-derived neurotrophic factor as a state-marker of mood episodes in bipolar disorders: A systematic review and meta-regression analysis. Journal of Psychiatric Research. 2011, 45(8): 995-1004.